Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BRISTOL MYERS SQUIBB COBMY · Entity 1662 | EVP & CSO | March 10, 2017 | March 15, 2017 |
| Rubius Therapeutics, Inc.RUBY · Entity 116417 | Director | May 12, 2022 | May 13, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BRISTOL MYERS SQUIBB CO
Report date March 10, 2017 · Filed March 15, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $0.10 par valueSEC Table I · non-derivative | Direct | 321,905.531 |
Ending reported balance
After 2017-03-10 transaction · row 14
14 source rows · reconciled sequenceRow 1 · 2017-03-10 · Exercise / conversion · Acquired 2,740 · Balance 292,471.531 F1: Represents vesting of one-quarter of market share units granted on March 10, 2013. Row 2 · 2017-03-10 · Other · Acquired 1,343 · Balance 293,814.531 F2: Adjustment reflects additional shares acquired upon the vesting of market share units due to the performance factor. Row 3 · 2017-03-10 · Tax withholding · Disposed 2,022 · Balance 291,792.531 F3: Shares withheld for payment of taxes upon vesting of awards. Row 4 · 2017-03-10 · Exercise / conversion · Acquired 5,279 · Balance 297,071.531 F4: Represents vesting of one-quarter of market share units granted on March 10, 2014. Row 5 · 2017-03-10 · Other · Acquired 41 · Balance 297,112.531 F2: Adjustment reflects additional shares acquired upon the vesting of market share units due to the performance factor. Row 6 · 2017-03-10 · Tax withholding · Disposed 2,759 · Balance 294,353.531 F3: Shares withheld for payment of taxes upon vesting of awards. Row 7 · 2017-03-10 · Exercise / conversion · Acquired 4,982 · Balance 299,335.531 F5: Represents vesting of one-quarter of market share units granted on March 10, 2015. Row 8 · 2017-03-10 · Other · Disposed 653 · Balance 298,682.531 F6: Represents a downward adjustment to the number of shares acquired upon the vesting of market share units due to the performance factor. Row 9 · 2017-03-10 · Tax withholding · Disposed 2,245 · Balance 296,437.531 F3: Shares withheld for payment of taxes upon vesting of awards. Row 10 · 2017-03-10 · Exercise / conversion · Acquired 5,772 · Balance 302,209.531 F7: Represents vesting of one-quarter of market share units granted on March 10, 2016. Row 11 · 2017-03-10 · Other · Disposed 831 · Balance 301,378.531 F6: Represents a downward adjustment to the number of shares acquired upon the vesting of market share units due to the performance factor. Row 12 · 2017-03-10 · Tax withholding · Disposed 2,562 · Balance 298,816.531 F3: Shares withheld for payment of taxes upon vesting of awards. Row 13 · 2017-03-10 · Exercise / conversion · Acquired 47,953 · Balance 346,769.531 F8: Amount represents distribution of performance shares earned under the 2014-2016 Long-Term Performance Award based on the performance factor applied in accordance with the terms of the Award and certification of performance results by the Board. Row 14 · 2017-03-10 · Tax withholding · Disposed 24,864 · Balance 321,905.531 F3: Shares withheld for payment of taxes upon vesting of awards. |
| Market Share UnitsSEC Table II · derivative / convertible security · Expires 2017-03-10 | Direct | 0 |
Reported balance
After 2017-03-10 transaction · row 15
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 15 · 2017-03-10 · Exercise / conversion · Disposed 2,740 · Balance 0 F9: Each market share unit converts into the number of shares of common stock determined by applying a payout factor to the target number of shares vesting on a given date. The payout factor is a ratio of the average of the closing price on the measurement date plus the nine prior trading days divided by the average stock price on the grant date (also a 10-day average). The minimum payout factor that must be achieved to earn a payout is 60% and the maximum payout factor is 200%. F1: Represents vesting of one-quarter of market share units granted on March 10, 2013. |
| Market Share UnitsSEC Table II · derivative / convertible security · Expires 2018-03-10 | Direct | 5,280 |
Reported balance
After 2017-03-10 transaction · row 16
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 16 · 2017-03-10 · Exercise / conversion · Disposed 5,279 · Balance 5,280 F9: Each market share unit converts into the number of shares of common stock determined by applying a payout factor to the target number of shares vesting on a given date. The payout factor is a ratio of the average of the closing price on the measurement date plus the nine prior trading days divided by the average stock price on the grant date (also a 10-day average). The minimum payout factor that must be achieved to earn a payout is 60% and the maximum payout factor is 200%. F4: Represents vesting of one-quarter of market share units granted on March 10, 2014. |
| Market Share UnitsSEC Table II · derivative / convertible security · Expires 2019-03-10 | Direct | 9,966 |
Reported balance
After 2017-03-10 transaction · row 17
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 17 · 2017-03-10 · Exercise / conversion · Disposed 4,982 · Balance 9,966 F9: Each market share unit converts into the number of shares of common stock determined by applying a payout factor to the target number of shares vesting on a given date. The payout factor is a ratio of the average of the closing price on the measurement date plus the nine prior trading days divided by the average stock price on the grant date (also a 10-day average). The minimum payout factor that must be achieved to earn a payout is 60% and the maximum payout factor is 200%. F5: Represents vesting of one-quarter of market share units granted on March 10, 2015. |
| Market Share UnitsSEC Table II · derivative / convertible security · Expires 2020-03-10 | Direct | 17,318 |
Reported balance
After 2017-03-10 transaction · row 18
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 18 · 2017-03-10 · Exercise / conversion · Disposed 5,772 · Balance 17,318 F9: Each market share unit converts into the number of shares of common stock determined by applying a payout factor to the target number of shares vesting on a given date. The payout factor is a ratio of the average of the closing price on the measurement date plus the nine prior trading days divided by the average stock price on the grant date (also a 10-day average). The minimum payout factor that must be achieved to earn a payout is 60% and the maximum payout factor is 200%. F7: Represents vesting of one-quarter of market share units granted on March 10, 2016. |
| Performance SharesSEC Table II · derivative / convertible security · Expires 2017-03-10 | Direct | 0 |
Reported balance
After 2017-03-10 transaction · row 19
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 19 · 2017-03-10 · Exercise / conversion · Disposed 47,953 · Balance 0 F10: Each performance share converts into one share of common stock upon distribution in the first quarter of 2017, subject to a Total Shareholder Return modifier. F8: Amount represents distribution of performance shares earned under the 2014-2016 Long-Term Performance Award based on the performance factor applied in accordance with the terms of the Award and certification of performance results by the Board. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents vesting of one-quarter of market share units granted on March 10, 2013.
F2: Adjustment reflects additional shares acquired upon the vesting of market share units due to the performance factor.
F3: Shares withheld for payment of taxes upon vesting of awards.
F4: Represents vesting of one-quarter of market share units granted on March 10, 2014.
F5: Represents vesting of one-quarter of market share units granted on March 10, 2015.
F6: Represents a downward adjustment to the number of shares acquired upon the vesting of market share units due to the performance factor.
F7: Represents vesting of one-quarter of market share units granted on March 10, 2016.
F8: Amount represents distribution of performance shares earned under the 2014-2016 Long-Term Performance Award based on the performance factor applied in accordance with the terms of the Award and certification of performance results by the Board.
F9: Each market share unit converts into the number of shares of common stock determined by applying a payout factor to the target number of shares vesting on a given date. The payout factor is a ratio of the average of the closing price on the measurement date plus the nine prior trading days divided by the average stock price on the grant date (also a 10-day average). The minimum payout factor that must be achieved to earn a payout is 60% and the maximum payout factor is 200%.
F10: Each performance share converts into one share of common stock upon distribution in the first quarter of 2017, subject to a Total Shareholder Return modifier.
Rubius Therapeutics, Inc.
Report date May 12, 2022 · Filed May 13, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.24 · Expires 2032-05-11 | Direct | 25,000 |
Reported balance
After 2022-05-12 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-05-12 · Grant · Acquired 25,000 · Balance 25,000 F1: This option shall vest in full on the earlier of (i) the one year anniversary of the grant date or (ii) the date of the next annual meeting of stockholders following the grant date, subject to the recipient's continued service. |
Filing footnotes · ownership attribution and instrument terms
F1: This option shall vest in full on the earlier of (i) the one year anniversary of the grant date or (ii) the date of the next annual meeting of stockholders following the grant date, subject to the recipient's continued service.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Mural Oncology plc
Report date December 05, 2025 · Filed December 05, 2025
Section 16 reporting ended · disclosed 2025-12-05. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.56 · Expires 2035-06-10 | Direct | 0 |
Reported balance
After 2025-12-05 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-12-05 · Disposition to issuer · Disposed 8,637 · Balance 0 F2: Pursuant to the terms of the Agreement, at the Effective Time each option to purchase ordinary shares of Issuer that had an exercise price per share that was equal to or greater than the Scheme Consideration was cancelled and ceased to be outstanding, and no Scheme Consideration was delivered in exchange for such options. F1: This Form 4 reports securities disposed of pursuant to the terms of the Transaction Agreement (the "Agreement"), dated August 20, 2025, by and among the Issuer, XRA 5 Corp. ("Sub"), a Delaware corporation and wholly-owned subsidiary of XOMA Royalty Corporation, a Nevada corporation, pursuant to which Sub acquired all the issued and to be issued share capital of the Issuer (the "Acquisition") for a cash purchase price of $2.035 per share (the "Scheme Consideration"). The Acquisition was completed as of December 5, 2025 (the "Effective Time"). |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.35 · Expires 2034-05-29 | Direct | 0 |
Reported balance
After 2025-12-05 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-12-05 · Disposition to issuer · Disposed 8,462 · Balance 0 F2: Pursuant to the terms of the Agreement, at the Effective Time each option to purchase ordinary shares of Issuer that had an exercise price per share that was equal to or greater than the Scheme Consideration was cancelled and ceased to be outstanding, and no Scheme Consideration was delivered in exchange for such options. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.61 · Expires 2033-12-13 | Direct | 0 |
Reported balance
After 2025-12-05 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2025-12-05 · Disposition to issuer · Disposed 15,021 · Balance 0 F2: Pursuant to the terms of the Agreement, at the Effective Time each option to purchase ordinary shares of Issuer that had an exercise price per share that was equal to or greater than the Scheme Consideration was cancelled and ceased to be outstanding, and no Scheme Consideration was delivered in exchange for such options. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of pursuant to the terms of the Transaction Agreement (the "Agreement"), dated August 20, 2025, by and among the Issuer, XRA 5 Corp. ("Sub"), a Delaware corporation and wholly-owned subsidiary of XOMA Royalty Corporation, a Nevada corporation, pursuant to which Sub acquired all the issued and to be issued share capital of the Issuer (the "Acquisition") for a cash purchase price of $2.035 per share (the "Scheme Consideration"). The Acquisition was completed as of December 5, 2025 (the "Effective Time").
F2: Pursuant to the terms of the Agreement, at the Effective Time each option to purchase ordinary shares of Issuer that had an exercise price per share that was equal to or greater than the Scheme Consideration was cancelled and ceased to be outstanding, and no Scheme Consideration was delivered in exchange for such options.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 05, 2025 Filed Dec 5, 2025 09:04 UTC | Mural Oncology plc MURA · Entity 72153 | Disposition to issuerStock Option (right to buy) · Derivative | 15,021 | Not disclosed Strike: $3.61 | Not disclosed |
DisclosureSEC source: 0001193125-25-308780 · ownership.xml · derivative · entry 3 Cuss Francis M · CIK 0001490216 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 15,021 shares Expires 2033-12-13 F2 · price: Pursuant to the terms of the Agreement, at the Effective Time each option to purchase ordinary shares of Issuer that had an exercise price per share that was equal to or greater than the Scheme Consideration was cancelled and ceased to be outstanding, and no Scheme Consideration was delivered in exchange for such options. F2 · derivative.exercise_date: Pursuant to the terms of the Agreement, at the Effective Time each option to purchase ordinary shares of Issuer that had an exercise price per share that was equal to or greater than the Scheme Consideration was cancelled and ceased to be outstanding, and no Scheme Consideration was delivered in exchange for such options. Read SEC document |
| December 05, 2025 Filed Dec 5, 2025 09:04 UTC | Mural Oncology plc MURA · Entity 72153 | Disposition to issuerStock Option (right to buy) · Derivative | 8,462 | Not disclosed Strike: $3.35 | Not disclosed |
DisclosureSEC source: 0001193125-25-308780 · ownership.xml · derivative · entry 2 Cuss Francis M · CIK 0001490216 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 8,462 shares Expires 2034-05-29 F2 · price: Pursuant to the terms of the Agreement, at the Effective Time each option to purchase ordinary shares of Issuer that had an exercise price per share that was equal to or greater than the Scheme Consideration was cancelled and ceased to be outstanding, and no Scheme Consideration was delivered in exchange for such options. F2 · derivative.exercise_date: Pursuant to the terms of the Agreement, at the Effective Time each option to purchase ordinary shares of Issuer that had an exercise price per share that was equal to or greater than the Scheme Consideration was cancelled and ceased to be outstanding, and no Scheme Consideration was delivered in exchange for such options. Read SEC document |
| December 05, 2025 Filed Dec 5, 2025 09:04 UTC | Mural Oncology plc MURA · Entity 72153 | Disposition to issuerStock Option (right to buy) · Derivative | 8,637 | Not disclosed Strike: $2.56 | Not disclosed |
DisclosureSEC source: 0001193125-25-308780 · ownership.xml · derivative · entry 1 Cuss Francis M · CIK 0001490216 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 8,637 shares Expires 2035-06-10 F2 · price: Pursuant to the terms of the Agreement, at the Effective Time each option to purchase ordinary shares of Issuer that had an exercise price per share that was equal to or greater than the Scheme Consideration was cancelled and ceased to be outstanding, and no Scheme Consideration was delivered in exchange for such options. F1 · derivative.exercise_date: This Form 4 reports securities disposed of pursuant to the terms of the Transaction Agreement (the "Agreement"), dated August 20, 2025, by and among the Issuer, XRA 5 Corp. ("Sub"), a Delaware corporation and wholly-owned subsidiary of XOMA Royalty Corporation, a Nevada corporation, pursuant to which Sub acquired all the issued and to be issued share capital of the Issuer (the "Acquisition") for a cash purchase price of $2.035 per share (the "Scheme Consideration"). The Acquisition was completed as of December 5, 2025 (the "Effective Time"). F2 · derivative.exercise_date: Pursuant to the terms of the Agreement, at the Effective Time each option to purchase ordinary shares of Issuer that had an exercise price per share that was equal to or greater than the Scheme Consideration was cancelled and ceased to be outstanding, and no Scheme Consideration was delivered in exchange for such options. Read SEC document |
| June 11, 2025 Filed Jun 13, 2025 08:00 UTC | Mural Oncology plc MURA · Entity 72153 | GrantStock Option (right to buy) · Derivative | 8,637 | $0.00 Strike: $2.56 | $0.00 |
DisclosureSEC source: 0000950170-25-085821 · ownership.xml · derivative · entry 1 Cuss Francis M · CIK 0001490216 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,637 Underlying: Ordinary Shares · 8,637 shares Expires 2035-06-10 F1 · derivative.exercise_date: This option was granted on June 11, 2025. This option will vest in full upon the earlier of (i) the first anniversary of the date of the grant or (ii) the date of the next Annual Meeting, subject to the reporting person's continued service with the Issuer. Read SEC document |
| May 30, 2024 Filed Jun 3, 2024 10:20 UTC | Mural Oncology plc MURA · Entity 72153 | GrantStock Option (right to buy) · Derivative | 8,462 | $3.35 Strike: $3.35 | $28,347.70 |
DisclosureSEC source: 0000950170-24-067712 · ownership.xml · derivative · entry 1 Cuss Francis M · CIK 0001490216 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,462 Underlying: Ordinary Shares · 8,462 shares Expires 2034-05-29 F1 · derivative.exercise_date: This option was granted on May 30, 2024. This option will vest in full upon the earlier of (i) the first anniversary of the date of the grant or (ii) the date of the next Annual Meeting, subject to the reporting person's continued service with the Issuer. Read SEC document |
| May 30, 2024 Filed Jun 5, 2024 16:13 UTC Amendment | Mural Oncology plc MURA · Entity 72153 | GrantStock Option (right to buy) · Derivative | 8,462 | $0.00 Strike: $3.35 | $0.00 |
DisclosureSEC source: 0000950170-24-069321 · ownership.xml · derivative · entry 1 Cuss Francis M · CIK 0001490216 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,462 Underlying: Ordinary Shares · 8,462 shares Expires 2034-05-29 F2 · price: This amendment to Form 4 is being filed solely to correct the price of the derivative security, which was previously reported as being $3.35 due to a scrivener's error. F1 · derivative.exercise_date: This option was granted on May 30, 2024. This option will vest in full upon the earlier of (i) the first anniversary of the date of the grant or (ii) the date of the next Annual Meeting, subject to the reporting person's continued service with the Issuer. Read SEC document |
| December 14, 2023 Filed Dec 18, 2023 16:30 UTC | Mural Oncology plc MURA · Entity 72153 | GrantStock Option (right to buy) · Derivative | 15,021 | $0.00 Strike: $3.61 | $0.00 |
DisclosureSEC source: 0000950170-23-071111 · ownership.xml · derivative · entry 1 Cuss Francis M · CIK 0001490216 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,021 Underlying: Ordinary Shares · 15,021 shares Expires 2033-12-13 F1 · derivative.exercise_date: This option was granted on December 14, 2023. This option shall vest over three years in twelve equal quarterly installments on each quarterly anniversary of October 31, 2023, subject to the reporting person's continued service with the Issuer. Read SEC document |
| May 12, 2022 Filed May 13, 2022 16:31 UTC | Rubius Therapeutics, Inc. RUBY · Entity 116417 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $1.24 | $0.00 |
DisclosureSEC source: 0001179110-22-003008 · edgar.xml · derivative · entry 1 Cuss Francis M · CIK 0001490216 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2032-05-11 F1 · derivative.exercise_date: This option shall vest in full on the earlier of (i) the one year anniversary of the grant date or (ii) the date of the next annual meeting of stockholders following the grant date, subject to the recipient's continued service. Read SEC document |
| May 12, 2021 Filed May 13, 2021 20:34 UTC | Rubius Therapeutics, Inc. RUBY · Entity 116417 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $23.25 | $0.00 |
DisclosureSEC source: 0001179110-21-005313 · edgar.xml · derivative · entry 1 Cuss Francis M · CIK 0001490216 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2031-05-11 F1 · derivative.exercise_date: This option shall vest in full on the earlier of (i) the one year anniversary of the grant date or (ii) the date of the next annual meeting of stockholders following the grant date, subject to the recipient's continued service. Read SEC document |
| May 21, 2020 Filed May 26, 2020 19:25 UTC | Rubius Therapeutics, Inc. RUBY · Entity 116417 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $6.22 | $0.00 |
DisclosureSEC source: 0001179110-20-006606 · edgar.xml · derivative · entry 1 Cuss Francis M · CIK 0001490216 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2030-05-20 F1 · derivative.exercise_date: This option shall vest in full on the earlier of (i) the one year anniversary of the grant date or (ii) the date of the next annual meeting of stockholders following the grant date, subject to the recipient's continued service. Read SEC document |
| May 23, 2019 Filed May 28, 2019 19:57 UTC | Rubius Therapeutics, Inc. RUBY · Entity 116417 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $16.27 | $0.00 |
DisclosureSEC source: 0001104659-19-032118 · a4.xml · derivative · entry 1 Cuss Francis M · CIK 0001490216 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2029-05-22 F1 · derivative.exercise_date: This option shall vest in full on the earlier of (i) the one year anniversary of the grant date or (ii) the date of the next annual meeting of stockholders following the grant date, subject to the recipient's continued service. Read SEC document |
| July 20, 2018 Filed Jul 23, 2018 16:33 UTC | Rubius Therapeutics, Inc. RUBY · Entity 116417 | PurchaseCommon Stock | 10,000 | $23.00 | $230,000.00 |
DisclosureSEC source: 0001104659-18-046528 · a4.xml · nonDerivative · entry 1 Cuss Francis M · CIK 0001490216 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Read SEC document |
| July 17, 2018 Filed Jul 18, 2018 16:32 UTC | Rubius Therapeutics, Inc. RUBY · Entity 116417 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $23.00 | $0.00 |
DisclosureSEC source: 0001104659-18-045772 · a4.xml · derivative · entry 1 Cuss Francis M · CIK 0001490216 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2028-07-16 F1 · derivative.exercise_date: This option shall vest in equal quarterly installments during the twelve quarters following the grant date. Read SEC document |
| March 10, 2017 Filed Mar 15, 2017 00:33 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Exercise / conversionPerformance Shares · Derivative | 47,953 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-17-000090 · wf-form4_148953796464775.xml · derivative · entry 19 Cuss Francis M · CIK 0001490216 · EVP & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, $0.10 par value · 47,953 shares Expires 2017-03-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F10 · derivative.exercise_price: Each performance share converts into one share of common stock upon distribution in the first quarter of 2017, subject to a Total Shareholder Return modifier. F8 · shares: Amount represents distribution of performance shares earned under the 2014-2016 Long-Term Performance Award based on the performance factor applied in accordance with the terms of the Award and certification of performance results by the Board. F10 · derivative.exercise_date: Each performance share converts into one share of common stock upon distribution in the first quarter of 2017, subject to a Total Shareholder Return modifier. F10 · derivative.expiration_date: Each performance share converts into one share of common stock upon distribution in the first quarter of 2017, subject to a Total Shareholder Return modifier. Read SEC document |
| March 10, 2017 Filed Mar 15, 2017 00:33 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Exercise / conversionMarket Share Units · Derivative | 5,772 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-17-000090 · wf-form4_148953796464775.xml · derivative · entry 18 Cuss Francis M · CIK 0001490216 · EVP & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,318 Underlying: Common Stock, $0.10 par value · 5,772 shares Expires 2020-03-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_price: Each market share unit converts into the number of shares of common stock determined by applying a payout factor to the target number of shares vesting on a given date. The payout factor is a ratio of the average of the closing price on the measurement date plus the nine prior trading days divided by the average stock price on the grant date (also a 10-day average). The minimum payout factor that must be achieved to earn a payout is 60% and the maximum payout factor is 200%. F7 · derivative.exercise_date: Represents vesting of one-quarter of market share units granted on March 10, 2016. F7 · derivative.expiration_date: Represents vesting of one-quarter of market share units granted on March 10, 2016. Read SEC document |
| March 10, 2017 Filed Mar 15, 2017 00:33 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Exercise / conversionMarket Share Units · Derivative | 4,982 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-17-000090 · wf-form4_148953796464775.xml · derivative · entry 17 Cuss Francis M · CIK 0001490216 · EVP & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,966 Underlying: Common Stock, $0.10 par value · 4,982 shares Expires 2019-03-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_price: Each market share unit converts into the number of shares of common stock determined by applying a payout factor to the target number of shares vesting on a given date. The payout factor is a ratio of the average of the closing price on the measurement date plus the nine prior trading days divided by the average stock price on the grant date (also a 10-day average). The minimum payout factor that must be achieved to earn a payout is 60% and the maximum payout factor is 200%. F5 · derivative.exercise_date: Represents vesting of one-quarter of market share units granted on March 10, 2015. F5 · derivative.expiration_date: Represents vesting of one-quarter of market share units granted on March 10, 2015. Read SEC document |
| March 10, 2017 Filed Mar 15, 2017 00:33 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Exercise / conversionMarket Share Units · Derivative | 5,279 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-17-000090 · wf-form4_148953796464775.xml · derivative · entry 16 Cuss Francis M · CIK 0001490216 · EVP & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,280 Underlying: Common Stock, $0.10 par value · 5,279 shares Expires 2018-03-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_price: Each market share unit converts into the number of shares of common stock determined by applying a payout factor to the target number of shares vesting on a given date. The payout factor is a ratio of the average of the closing price on the measurement date plus the nine prior trading days divided by the average stock price on the grant date (also a 10-day average). The minimum payout factor that must be achieved to earn a payout is 60% and the maximum payout factor is 200%. F4 · derivative.exercise_date: Represents vesting of one-quarter of market share units granted on March 10, 2014. F4 · derivative.expiration_date: Represents vesting of one-quarter of market share units granted on March 10, 2014. Read SEC document |
| March 10, 2017 Filed Mar 15, 2017 00:33 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Exercise / conversionMarket Share Units · Derivative | 2,740 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-17-000090 · wf-form4_148953796464775.xml · derivative · entry 15 Cuss Francis M · CIK 0001490216 · EVP & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, $0.10 par value · 2,740 shares Expires 2017-03-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_price: Each market share unit converts into the number of shares of common stock determined by applying a payout factor to the target number of shares vesting on a given date. The payout factor is a ratio of the average of the closing price on the measurement date plus the nine prior trading days divided by the average stock price on the grant date (also a 10-day average). The minimum payout factor that must be achieved to earn a payout is 60% and the maximum payout factor is 200%. F1 · derivative.exercise_date: Represents vesting of one-quarter of market share units granted on March 10, 2013. F1 · derivative.expiration_date: Represents vesting of one-quarter of market share units granted on March 10, 2013. Read SEC document |
| March 10, 2017 Filed Mar 15, 2017 00:33 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Tax withholdingCommon Stock, $0.10 par value | 24,864 | $58.32 | $1,450,068.48 |
DisclosureSEC source: 0000014272-17-000090 · wf-form4_148953796464775.xml · nonDerivative · entry 14 Cuss Francis M · CIK 0001490216 · EVP & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 321,905.531 F3 · shares: Shares withheld for payment of taxes upon vesting of awards. Read SEC document |
| March 10, 2017 Filed Mar 15, 2017 00:33 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Exercise / conversionCommon Stock, $0.10 par value | 47,953 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-17-000090 · wf-form4_148953796464775.xml · nonDerivative · entry 13 Cuss Francis M · CIK 0001490216 · EVP & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 346,769.531 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · shares: Amount represents distribution of performance shares earned under the 2014-2016 Long-Term Performance Award based on the performance factor applied in accordance with the terms of the Award and certification of performance results by the Board. Read SEC document |
| March 10, 2017 Filed Mar 15, 2017 00:33 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Tax withholdingCommon Stock, $0.10 par value | 2,562 | $58.32 | $149,415.84 |
DisclosureSEC source: 0000014272-17-000090 · wf-form4_148953796464775.xml · nonDerivative · entry 12 Cuss Francis M · CIK 0001490216 · EVP & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 298,816.531 F3 · shares: Shares withheld for payment of taxes upon vesting of awards. Read SEC document |
| March 10, 2017 Filed Mar 15, 2017 00:33 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | OtherCommon Stock, $0.10 par value | 831 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-17-000090 · wf-form4_148953796464775.xml · nonDerivative · entry 11 Cuss Francis M · CIK 0001490216 · EVP & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 301,378.531 F6 · shares: Represents a downward adjustment to the number of shares acquired upon the vesting of market share units due to the performance factor. Read SEC document |
| March 10, 2017 Filed Mar 15, 2017 00:33 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Exercise / conversionCommon Stock, $0.10 par value | 5,772 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-17-000090 · wf-form4_148953796464775.xml · nonDerivative · entry 10 Cuss Francis M · CIK 0001490216 · EVP & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 302,209.531 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · shares: Represents vesting of one-quarter of market share units granted on March 10, 2016. Read SEC document |
| March 10, 2017 Filed Mar 15, 2017 00:33 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Tax withholdingCommon Stock, $0.10 par value | 2,245 | $58.32 | $130,928.40 |
DisclosureSEC source: 0000014272-17-000090 · wf-form4_148953796464775.xml · nonDerivative · entry 9 Cuss Francis M · CIK 0001490216 · EVP & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 296,437.531 F3 · shares: Shares withheld for payment of taxes upon vesting of awards. Read SEC document |
| March 10, 2017 Filed Mar 15, 2017 00:33 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | OtherCommon Stock, $0.10 par value | 653 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-17-000090 · wf-form4_148953796464775.xml · nonDerivative · entry 8 Cuss Francis M · CIK 0001490216 · EVP & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 298,682.531 F6 · shares: Represents a downward adjustment to the number of shares acquired upon the vesting of market share units due to the performance factor. Read SEC document |
| March 10, 2017 Filed Mar 15, 2017 00:33 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Exercise / conversionCommon Stock, $0.10 par value | 4,982 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-17-000090 · wf-form4_148953796464775.xml · nonDerivative · entry 7 Cuss Francis M · CIK 0001490216 · EVP & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 299,335.531 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · shares: Represents vesting of one-quarter of market share units granted on March 10, 2015. Read SEC document |
| March 10, 2017 Filed Mar 15, 2017 00:33 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Tax withholdingCommon Stock, $0.10 par value | 2,759 | $58.32 | $160,904.88 |
DisclosureSEC source: 0000014272-17-000090 · wf-form4_148953796464775.xml · nonDerivative · entry 6 Cuss Francis M · CIK 0001490216 · EVP & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 294,353.531 F3 · shares: Shares withheld for payment of taxes upon vesting of awards. Read SEC document |
| March 10, 2017 Filed Mar 15, 2017 00:33 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | OtherCommon Stock, $0.10 par value | 41 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-17-000090 · wf-form4_148953796464775.xml · nonDerivative · entry 5 Cuss Francis M · CIK 0001490216 · EVP & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 297,112.531 F2 · shares: Adjustment reflects additional shares acquired upon the vesting of market share units due to the performance factor. Read SEC document |
| March 10, 2017 Filed Mar 15, 2017 00:33 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Exercise / conversionCommon Stock, $0.10 par value | 5,279 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-17-000090 · wf-form4_148953796464775.xml · nonDerivative · entry 4 Cuss Francis M · CIK 0001490216 · EVP & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 297,071.531 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · shares: Represents vesting of one-quarter of market share units granted on March 10, 2014. Read SEC document |
| March 10, 2017 Filed Mar 15, 2017 00:33 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Tax withholdingCommon Stock, $0.10 par value | 2,022 | $58.32 | $117,923.04 |
DisclosureSEC source: 0000014272-17-000090 · wf-form4_148953796464775.xml · nonDerivative · entry 3 Cuss Francis M · CIK 0001490216 · EVP & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 291,792.531 F3 · shares: Shares withheld for payment of taxes upon vesting of awards. Read SEC document |
| March 10, 2017 Filed Mar 15, 2017 00:33 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | OtherCommon Stock, $0.10 par value | 1,343 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-17-000090 · wf-form4_148953796464775.xml · nonDerivative · entry 2 Cuss Francis M · CIK 0001490216 · EVP & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 293,814.531 F2 · shares: Adjustment reflects additional shares acquired upon the vesting of market share units due to the performance factor. Read SEC document |
| March 10, 2017 Filed Mar 15, 2017 00:33 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Exercise / conversionCommon Stock, $0.10 par value | 2,740 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-17-000090 · wf-form4_148953796464775.xml · nonDerivative · entry 1 Cuss Francis M · CIK 0001490216 · EVP & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 292,471.531 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents vesting of one-quarter of market share units granted on March 10, 2013. Read SEC document |
| July 01, 2016 Filed Jul 6, 2016 21:58 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Exercise / conversionRestricted Stock Units · Derivative | 3,655 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-16-000452 · wf-form4_146784232428841.xml · derivative · entry 3 Cuss Francis M · CIK 0001490216 · EVP & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,308 Underlying: Common Stock, $0.10 par value · 3,655 shares Expires 2018-07-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit converts into one share of common stock upon vesting. F3 · shares: Represents vesting of one third of restricted stock units granted on July 1, 2013. The balance of the award is scheduled to to vest in two equal installments on the fourth and fifth anniversaries of the grant date. F3 · derivative.exercise_date: Represents vesting of one third of restricted stock units granted on July 1, 2013. The balance of the award is scheduled to to vest in two equal installments on the fourth and fifth anniversaries of the grant date. Read SEC document |
| July 01, 2016 Filed Jul 6, 2016 21:58 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Tax withholdingCommon Stock, $0.10 par value | 1,896 | $73.78 | $139,886.88 |
DisclosureSEC source: 0000014272-16-000452 · wf-form4_146784232428841.xml · nonDerivative · entry 2 Cuss Francis M · CIK 0001490216 · EVP & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 289,731.5285 F1 · shares: Shares withheld for payment of taxes upon vesting of awards. Read SEC document |
| July 01, 2016 Filed Jul 6, 2016 21:58 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Exercise / conversionCommon Stock, $0.10 par value | 3,655 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-16-000452 · wf-form4_146784232428841.xml · nonDerivative · entry 1 Cuss Francis M · CIK 0001490216 · EVP & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 291,627.5285 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 10, 2016 Filed Mar 15, 2016 01:43 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Exercise / conversionPerformance Shares · Derivative | 24,142.158 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-16-000367 · wf-form4_145800619241839.xml · derivative · entry 19 Cuss Francis M · CIK 0001490216 · EVP & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, $0.10 par value · 24,142.158 shares Expires 2016-03-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F11 · derivative.exercise_price: Each performance share converts into one share of common stock upon distribution in the first quarter of 2016. F7 · shares: Represents distribution of performance shares earned under the 2013-2015 Long-Term Performance Award. F11 · derivative.exercise_date: Each performance share converts into one share of common stock upon distribution in the first quarter of 2016. F11 · derivative.expiration_date: Each performance share converts into one share of common stock upon distribution in the first quarter of 2016. Read SEC document |
| March 10, 2016 Filed Mar 15, 2016 01:43 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | OtherPerformance Shares · Derivative | 553.478 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-16-000367 · wf-form4_145800619241839.xml · derivative · entry 18 Cuss Francis M · CIK 0001490216 · EVP & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,142.158 Underlying: Common Stock, $0.10 par value · 553.478 shares Expires 2016-03-31 F13 · derivative.exercise_price: Each dividend equivalent converts into one share of common stock upon distribution in the first quarter of 2016. F14 · shares: Represents dividend equivalents earned under the 2013-2015 Long-Term Performance Award. F13 · derivative.exercise_date: Each dividend equivalent converts into one share of common stock upon distribution in the first quarter of 2016. F13 · derivative.expiration_date: Each dividend equivalent converts into one share of common stock upon distribution in the first quarter of 2016. Read SEC document |
| March 10, 2016 Filed Mar 15, 2016 01:43 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantPerformance Shares · Derivative | 9,177.325 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-16-000367 · wf-form4_145800619241839.xml · derivative · entry 17 Cuss Francis M · CIK 0001490216 · EVP & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,588.68 Underlying: Common Stock, $0.10 par value · 9,177.325 shares Expires 2016-03-31 F11 · derivative.exercise_price: Each performance share converts into one share of common stock upon distribution in the first quarter of 2016. F12 · shares: Represents performance shares earned under the 2013-2015 Long-Term Performance Award. F11 · derivative.exercise_date: Each performance share converts into one share of common stock upon distribution in the first quarter of 2016. F11 · derivative.expiration_date: Each performance share converts into one share of common stock upon distribution in the first quarter of 2016. Read SEC document |
| March 10, 2016 Filed Mar 15, 2016 01:43 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantPerformance Shares · Derivative | 34,634 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-16-000367 · wf-form4_145800619241839.xml · derivative · entry 16 Cuss Francis M · CIK 0001490216 · EVP & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,634 Underlying: Common Stock, $0.10 par value · 34,634 shares Expires 2019-03-10 F10 · derivative.exercise_price: Each performance share converts into one share of common stock upon distribution in the first quarter of 2019. F10 · derivative.exercise_date: Each performance share converts into one share of common stock upon distribution in the first quarter of 2019. F10 · derivative.expiration_date: Each performance share converts into one share of common stock upon distribution in the first quarter of 2019. Read SEC document |
| March 10, 2016 Filed Mar 15, 2016 01:43 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantMarket Share Units · Derivative | 23,090 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-16-000367 · wf-form4_145800619241839.xml · derivative · entry 15 Cuss Francis M · CIK 0001490216 · EVP & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,090 Underlying: Common Stock, $0.10 par value · 23,090 shares Expires 2020-03-10 F8 · derivative.exercise_price: Each market share unit converts into the number of shares of common stock determined by applying a payout factor to the target number of shares vesting on a given date. The payout factor is a ratio of the average of the closing price on the measurement date plus the nine prior trading days divided by the average stock price on the grant date (also a 10-day average). The minimum payout factor that must be achieved to earn a payout is 60% and the maximum payout factor is 200%. F9 · derivative.exercise_date: Twenty-five percent of the market share unit award will vest on each of the first, second, third and fourth anniversaries of the grant date. F9 · derivative.expiration_date: Twenty-five percent of the market share unit award will vest on each of the first, second, third and fourth anniversaries of the grant date. Read SEC document |
| March 10, 2016 Filed Mar 15, 2016 01:43 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Exercise / conversionMarket Share Units · Derivative | 4,982 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-16-000367 · wf-form4_145800619241839.xml · derivative · entry 14 Cuss Francis M · CIK 0001490216 · EVP & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,948 Underlying: Common Stock, $0.10 par value · 4,982 shares Expires 2019-03-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_price: Each market share unit converts into the number of shares of common stock determined by applying a payout factor to the target number of shares vesting on a given date. The payout factor is a ratio of the average of the closing price on the measurement date plus the nine prior trading days divided by the average stock price on the grant date (also a 10-day average). The minimum payout factor that must be achieved to earn a payout is 60% and the maximum payout factor is 200%. F5 · derivative.exercise_date: Represents vesting of one-quarter of market share units granted on March 10, 2015. F5 · derivative.expiration_date: Represents vesting of one-quarter of market share units granted on March 10, 2015. Read SEC document |
| March 10, 2016 Filed Mar 15, 2016 01:43 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Exercise / conversionMarket Share Units · Derivative | 5,280 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-16-000367 · wf-form4_145800619241839.xml · derivative · entry 13 Cuss Francis M · CIK 0001490216 · EVP & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,559 Underlying: Common Stock, $0.10 par value · 5,280 shares Expires 2018-03-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_price: Each market share unit converts into the number of shares of common stock determined by applying a payout factor to the target number of shares vesting on a given date. The payout factor is a ratio of the average of the closing price on the measurement date plus the nine prior trading days divided by the average stock price on the grant date (also a 10-day average). The minimum payout factor that must be achieved to earn a payout is 60% and the maximum payout factor is 200%. F4 · derivative.exercise_date: Represents vesting of one-quarter of market share units granted on March 10, 2014. F4 · derivative.expiration_date: Represents vesting of one-quarter of market share units granted on March 10, 2014. Read SEC document |
| March 10, 2016 Filed Mar 15, 2016 01:43 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Exercise / conversionMarket Share Units · Derivative | 2,739 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-16-000367 · wf-form4_145800619241839.xml · derivative · entry 12 Cuss Francis M · CIK 0001490216 · EVP & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,740 Underlying: Common Stock, $0.10 par value · 2,739 shares Expires 2017-03-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_price: Each market share unit converts into the number of shares of common stock determined by applying a payout factor to the target number of shares vesting on a given date. The payout factor is a ratio of the average of the closing price on the measurement date plus the nine prior trading days divided by the average stock price on the grant date (also a 10-day average). The minimum payout factor that must be achieved to earn a payout is 60% and the maximum payout factor is 200%. F1 · derivative.exercise_date: Represents vesting of one-quarter of market share units granted on March 10, 2013. F1 · derivative.expiration_date: Represents vesting of one-quarter of market share units granted on March 10, 2013. Read SEC document |
| March 10, 2016 Filed Mar 15, 2016 01:43 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Tax withholdingCommon Stock, $0.10 par value | 12,519 | $64.94 | $812,983.86 |
DisclosureSEC source: 0000014272-16-000367 · wf-form4_145800619241839.xml · nonDerivative · entry 11 Cuss Francis M · CIK 0001490216 · EVP & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 287,972.5285 F3 · shares: Shares withheld for payment of taxes upon vesting of awards. Read SEC document |
| March 10, 2016 Filed Mar 15, 2016 01:43 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Exercise / conversionCommon Stock, $0.10 par value | 24,142.158 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-16-000367 · wf-form4_145800619241839.xml · nonDerivative · entry 10 Cuss Francis M · CIK 0001490216 · EVP & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,491.5285 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · shares: Represents distribution of performance shares earned under the 2013-2015 Long-Term Performance Award. Read SEC document |
| March 10, 2016 Filed Mar 15, 2016 01:43 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Tax withholdingCommon Stock, $0.10 par value | 2,543 | $64.94 | $165,142.42 |
DisclosureSEC source: 0000014272-16-000367 · wf-form4_145800619241839.xml · nonDerivative · entry 9 Cuss Francis M · CIK 0001490216 · EVP & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 276,349.3705 F3 · shares: Shares withheld for payment of taxes upon vesting of awards. Read SEC document |
| March 10, 2016 Filed Mar 15, 2016 01:43 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | OtherCommon Stock, $0.10 par value | 78 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-16-000367 · wf-form4_145800619241839.xml · nonDerivative · entry 8 Cuss Francis M · CIK 0001490216 · EVP & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 278,892.3705 F6 · shares: Represents a downward adjustment to the number of shares acquired upon the vesting of market share units due to the performance factor. Read SEC document |
| March 10, 2016 Filed Mar 15, 2016 01:43 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Exercise / conversionCommon Stock, $0.10 par value | 4,982 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-16-000367 · wf-form4_145800619241839.xml · nonDerivative · entry 7 Cuss Francis M · CIK 0001490216 · EVP & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 278,970.3705 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · shares: Represents vesting of one-quarter of market share units granted on March 10, 2015. Read SEC document |
| March 10, 2016 Filed Mar 15, 2016 01:43 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Tax withholdingCommon Stock, $0.10 par value | 3,126 | $64.94 | $203,002.44 |
DisclosureSEC source: 0000014272-16-000367 · wf-form4_145800619241839.xml · nonDerivative · entry 6 Cuss Francis M · CIK 0001490216 · EVP & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 273,988.3705 F3 · shares: Shares withheld for payment of taxes upon vesting of awards. Read SEC document |
| March 10, 2016 Filed Mar 15, 2016 01:43 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | OtherCommon Stock, $0.10 par value | 747 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-16-000367 · wf-form4_145800619241839.xml · nonDerivative · entry 5 Cuss Francis M · CIK 0001490216 · EVP & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 277,114.3705 F2 · shares: Adjustment reflects additional shares acquired upon the vesting of market share units due to the performance factor. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.